Tags

Type your tag names separated by a space and hit enter

Novel biomarkers of overactive bladder syndrome.
Ginekol Pol. 2017; 88(10):568-573.GP

Abstract

The social aspect of overactive bladder syndrome (OAB) and the lack of objective diagnostic methods for this syndrome have spurred research into its potential biomarkers which can constitute useful diagnostic tools, while also allowing the evaluation of the intensity of clinical symptoms and the efficacy of implemented pharmacotherapy in OAB patients. Due to the complex etiopathogenesis of this syndrome, the researchers are seeking biomarkers connected with inflammation or nerve growth. The aim of this review was to analyse the latest literature data regarding potential biomarkers in OAB. The most promising opportunities are connected with the diagnostic use of the nerve growth factor (NGF), the brain derived neurotrophic factor (BDNF), C-reactive protein (CRP), prostaglandins and cytokines. Despite the most promising results to date having been obtained with regards to neurotrophic factors, it seems that, at the moment, none of these meets the criteria for becoming an isolated OAB marker. It is also suggested that the combined use of several biomarkers will facilitate obtaining the appropriate level of specificity and selectivity to allow their use in clinical practice.

Authors+Show Affiliations

Second Department of Gynecology, Medical University of Lublin,, Jaczewskiego 8, PL 20-090 Lublin, Poland, 20-090, Lublin, Poland. wrobelandrzej@yahoo.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29192418

Citation

Wróbel, Andrzej Franciszek, et al. "Novel Biomarkers of Overactive Bladder Syndrome." Ginekologia Polska, vol. 88, no. 10, 2017, pp. 568-573.
Wróbel AF, Kluz T, Surkont G, et al. Novel biomarkers of overactive bladder syndrome. Ginekol Pol. 2017;88(10):568-573.
Wróbel, A. F., Kluz, T., Surkont, G., Wlaźlak, E., Skorupski, P., Filipczak, A., & Rechberger, T. (2017). Novel biomarkers of overactive bladder syndrome. Ginekologia Polska, 88(10), 568-573. https://doi.org/10.5603/GP.a2017.0102
Wróbel AF, et al. Novel Biomarkers of Overactive Bladder Syndrome. Ginekol Pol. 2017;88(10):568-573. PubMed PMID: 29192418.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel biomarkers of overactive bladder syndrome. AU - Wróbel,Andrzej Franciszek, AU - Kluz,Tomasz, AU - Surkont,Grzegorz, AU - Wlaźlak,Edyta, AU - Skorupski,Paweł, AU - Filipczak,Aleksandra, AU - Rechberger,Tomasz, PY - 2017/09/01/received PY - 2017/10/10/accepted PY - 2017/10/08/revised PY - 2017/12/2/entrez PY - 2017/12/2/pubmed PY - 2018/7/13/medline KW - biomarker KW - diagnosis KW - overactive bladder SP - 568 EP - 573 JF - Ginekologia polska JO - Ginekol Pol VL - 88 IS - 10 N2 - The social aspect of overactive bladder syndrome (OAB) and the lack of objective diagnostic methods for this syndrome have spurred research into its potential biomarkers which can constitute useful diagnostic tools, while also allowing the evaluation of the intensity of clinical symptoms and the efficacy of implemented pharmacotherapy in OAB patients. Due to the complex etiopathogenesis of this syndrome, the researchers are seeking biomarkers connected with inflammation or nerve growth. The aim of this review was to analyse the latest literature data regarding potential biomarkers in OAB. The most promising opportunities are connected with the diagnostic use of the nerve growth factor (NGF), the brain derived neurotrophic factor (BDNF), C-reactive protein (CRP), prostaglandins and cytokines. Despite the most promising results to date having been obtained with regards to neurotrophic factors, it seems that, at the moment, none of these meets the criteria for becoming an isolated OAB marker. It is also suggested that the combined use of several biomarkers will facilitate obtaining the appropriate level of specificity and selectivity to allow their use in clinical practice. SN - 0017-0011 UR - https://www.unboundmedicine.com/medline/citation/29192418/Novel_biomarkers_of_overactive_bladder_syndrome_ L2 - https://journals.viamedica.pl/ginekologia_polska/article/view/55086 DB - PRIME DP - Unbound Medicine ER -